Regression of Atherosclerosis by Amlodipine via Anti-Inflammatory and Anti-Oxidative Stress Actions

We examined whether amlodipine, an L-type calcium channel blocker (CCB), has an inhibitory effect on oxidative stress and inflammatory response, and thereby atherosclerosis, in apolipoprotein E–deficient (ApoEKO) mice. Adult male ApoEKO mice (6 weeks of age) were fed a high-cholesterol diet (HCD) for 8 or 10 weeks with or without oral administration of amlodipine (3 mg/kg/day) for 10 weeks or for only the last 2 weeks of the HCD. After HCD feeding, atherosclerotic lesion formation, in situ superoxide production and nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase activity were evaluated in the proximal aorta. The expressions of NADPH oxidase subunits (p47phox and rac-1), monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) were determined with immunohistochemistry and quantitative real-time reverse-transcription polymerase chain reaction. After 8 to 10 weeks of HCD administration to ApoEKO mice, marked atherosclerotic lesion formation was observed in the proximal aorta. In the atherosclerotic lesion, superoxide production, the expression of NADPH oxidase subunits, and NADPH oxidase activity were enhanced, and the expressions of MCP-1, ICAM-1, and VCAM-1 were increased. These changes were suppressed in mice that were treated with amlodipine for 10 weeks concomitant with HCD administration, with no significant change in blood pressure and plasma cholesterol level. We also observed that treatment with amlodipine for only the last 2 weeks regressed the atherosclerotic lesions with a decrease in oxidative stress and vascular inflammation. Inhibition of the atherosclerotic lesion area and lipid area in the proximal aorta by amlodipine was correlated with its inhibitory actions on oxidative stress, inflammation and the production of adhesive molecules. These results suggest that amlodipine not only inhibits atherosclerotic lesion formation, but also regresses atherosclerosis, and that these effects are at least partly due to inhibition of oxidative stress and inflammatory response.

[1]  I. Tabas Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis: The Importance of Lesion Stage and Phagocytic Efficiency , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[2]  T. Godfraind,et al.  Calcium Channel Blocker Inhibits Western-Type Diet-Evoked Atherosclerosis Development in ApoE-Deficient Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[3]  R. Chen,et al.  Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein , 2005 .

[4]  Takahiro Shimizu,et al.  Calcium Channel Blockades Exhibit Anti-Inflammatory and Antioxidative Effects by Augmentation of Endothelial Nitric Oxide Synthase and the Inhibition of Angiotensin Converting Enzyme in the NG-Nitro-L-Arginine Methyl Ester-Induced Hypertensive Rat Aorta: Vasoprotective Effects beyond the Blood Press , 2005, Hypertension Research.

[5]  Jian-Mei Li,et al.  Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice , 2005, Journal of hypertension.

[6]  T. Ishimitsu,et al.  Protective Effects of an Angiotensin II Receptor Blocker and a Long-Acting Calcium Channel Blocker against Cardiovascular Organ Injuries in Hypertensive Patients , 2005, Hypertension Research.

[7]  P. Libby,et al.  Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .

[8]  M. Matsuzaki,et al.  Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[9]  C. Zancanaro,et al.  Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study. , 2004, Toxicologic pathology.

[10]  S. Takai,et al.  Comparative effects of candesartan and amlodipine in a monkey atherosclerotic model. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[11]  G. Mancia,et al.  Absolute and relative changes in carotid intima–media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA) , 2004, Journal of hypertension.

[12]  D. Ausiello,et al.  Differential expression and targeting of endogenous Arf1 and Arf6 small GTPases in kidney epithelial cells in situ. , 2004, American journal of physiology. Cell physiology.

[13]  M. Cooper,et al.  Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis , 2004, Circulation.

[14]  A. Takeshita,et al.  Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. , 2004, American journal of physiology. Heart and circulatory physiology.

[15]  F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[16]  J. Staessen,et al.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.

[17]  Tomoya Yamashita,et al.  Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. , 2002, The Journal of clinical investigation.

[18]  Ding-liang Zhu,et al.  Dual mechanism of action of amlodipine in human vascular smooth muscle cells , 2002, Journal of hypertension.

[19]  J. Wilcox,et al.  Upregulation of Nox‐Based NAD(P)H Oxidases in Restenosis After Carotid Injury , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  S. Holland,et al.  p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. , 2001, The Journal of clinical investigation.

[21]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[22]  D. Sorescu,et al.  Novel gp91phox Homologues in Vascular Smooth Muscle Cells: nox1 Mediates Angiotensin II-Induced Superoxide Formation and Redox-Sensitive Signaling Pathways , 2001, Circulation research.

[23]  D. Weiss,et al.  Angiotensin II–Induced Hypertension Accelerates the Development of Atherosclerosis in ApoE-Deficient Mice , 2001, Circulation.

[24]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[25]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[26]  W. R. Taylor,et al.  Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumor necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  G. Gaviraghi,et al.  Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. , 1999, Journal of hypertension.

[28]  S. Dhein,et al.  Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. , 1999, Circulation.

[29]  N. Kobayashi,et al.  Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. , 1999, Journal of cardiovascular pharmacology.

[30]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[31]  K. Irani,et al.  Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. , 1999, American journal of physiology. Cell physiology.

[32]  E. Schiffrin,et al.  Apoptosis in vasculature of spontaneously hypertensive rats: effect of an angiotensin converting enzyme inhibitor and a calcium channel antagonist. , 1998, American journal of hypertension.

[33]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[34]  T. Hintze,et al.  Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. , 1998, Circulation.

[35]  T. Saldeen,et al.  Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. , 1997, Journal of the American College of Cardiology.

[36]  T. Nosek,et al.  Increased superoxide production during fatigue in the perfused rat diaphragm. , 1997, American journal of respiratory and critical care medicine.

[37]  P. Erne,et al.  Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Qiao,et al.  Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. , 1994, The Journal of clinical investigation.

[39]  M. Cathcart,et al.  Dual Ca2+ requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. , 1993, The Journal of clinical investigation.

[40]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[41]  J. Wouter Jukema,et al.  Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. , 2003, Journal of molecular and cellular cardiology.